John Rountree discusses, on CNBC, Novartis financial results, pharma innovation and how acquisitions in Big Pharma are still a hot topic
Novasecta’s Principal, Ed Corbett, was asked by The Pharma Letter, in a special report piece, to consider an issue of paramount importance to the future of the industry: AI
Artificial intelligence (AI) has the potential to provide huge benefits to the pharmaceutical industry, from improving R&D productivity through to more effective sales representative deployment and better supply chain management.
Adoption of AI is lagging other sectors, with initial forays mainly being led by big pharma, with its deep pockets and willingness to try new innovations. For many, however, it remains misunderstood, or even feared.
Given the transformative potential of AI, companies must at the very least understand its benefits and develop a strategy that meets each organization’s unique situation
We have worked collaboratively with Novasecta over many years across a range of strategic topics. I have particularly valued how they really understand and care about our business, and how they manage to apply their deep industry insights to our context. This has brought my Management Team and Board to clarity and alignment on practical strategic moves at important moments in our evolution as a company.CEO – Biotech